Cure Liver Infection and Hepatitis B Instead of Managing It
Gene Targeting for the treatment of HBV and HDV
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
This technology combines current hepatitis B treatments with a new method targeting the virus's surface antigen, offering a potential cure for liver infection and diseases by preventing antigen expression and virus infectivity. It also implicitly treats hepatitis D by targeting its dependent, hepatitis B. This dual-action approach shows promise for a functional cure in early trials.
IP Type or Form Factor: Patent Pending; Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Pharmaceutical Engineering; Healthcare Provider
